Results 211 to 220 of about 1,615,435 (305)

Adenosine receptor subtype modulators: Insight into molecular mechanisms and their therapeutic application. [PDF]

open access: yesAm J Transl Res
Solanki N   +14 more
europepmc   +1 more source

Astrocyte SMN Restoration and Forskolin Treatment Improve SMA Synaptic Pathology

open access: yesAnnals of Neurology, EarlyView.
Objective Early phenotypic presentation of central afferent synapse dysfunction within patients with spinal muscular atrophy (SMA) represents a key target for therapeutic development; however, the underlying disease mechanisms remain unresolved. By further investigating motor neuron synapse and peri‐synaptic astrocyte process (PAP) defects in human SMA
Emily Welby   +6 more
wiley   +1 more source

dsRADAR: Imaging and Detecting Cellular dsRNA by Repurposing RNA‐Binding Proteins

open access: yesAngewandte Chemie, EarlyView.
Double‐stranded RNA (dsRNA) plays an important role in the innate immune system, but can be misregulated in disease, leading to inflammation. Despite the importance of this motif, methods for detecting dsRNA remain limited. This work shows that ADAR3 can be repurposed to provide improved detection of dsRNA, which is demonstrated in the context of viral
Weina Cheng   +7 more
wiley   +2 more sources

Biomimetic Nanomedicine for Aging‐Impaired Bone Regeneration: From Microenvironmental Dysfunction to Precision Therapeutics

open access: yesAdvanced NanoBiomed Research, EarlyView.
Aging disrupts the cellular, immune, vascular, and neural processes required for bone regeneration. This review connects these pathological barriers with biomimetic nanomedicine design, highlighting strategies for cellular rejuvenation, immune modulation, vascular regeneration, and neuro–bone coupling.
Zeyu Wang   +12 more
wiley   +1 more source

A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson's Disease. [PDF]

open access: yesCells
Spinaci A   +10 more
europepmc   +1 more source

First-in-human study of the dual A<sub>2</sub><sub>A</sub>/A<sub>2</sub><sub>B</sub> adenosine receptor antagonist muvadenant (M1069) in patients with advanced solid tumors. [PDF]

open access: yesESMO Open
Siu LL   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy